| Previous Close | 1.64 |
| Open | 1.60 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 1.60 - 1.68 |
| 52 Week Range | 0.74 - 1.92 |
| Volume | 322,375 |
| Avg. Volume | 665,743 |
| Market Cap | 231.41M |
| Beta | 2.05 |
| PE Ratio (TTM) | -6.29 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Thomson Reuters StreetEvents•5 days ago
Edited Transcript of DRRX earnings conference call or presentation 8-Aug-17 8:30pm GMT
Q2 2017 DURECT Corp Earnings Call
- Zacks Small Cap Research•9 days ago
DRRX: A $293 Million Deal with Sandoz for POSIMIR® in the United States
On May 8, 2017, Durect (DRRX) announced a development and commercialization agreement with Sandoz AG, a division of Novartis (NVS), to develop and market in the United States Durect’s POSIMIR® (SABER®-Bupivacaine), an investigational locally-acting, non-opioid analgesic intended to provide up to three days of continuous pain relief after surgery. Under the terms of the agreement, Sandoz will make an upfront payment to DURECT of $20 million, with the potential for up to an additional $43 million in development and regulatory milestones, up to an additional $230 million in sales based milestones, as well as a tiered double digit royalty on product sales in the United States. The $43 million could be received when Durect resubmits the NDA and get approval for Posimir which could be done in 1Q18.
- Associated Press•11 days ago
Durect reports 2Q loss
On a per-share basis, the Cupertino, California-based company said it had a loss of 7 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...
